Advertisements

Dualid (ANTIULCER)

Quick links to important sections

Dualid (ANTIULCER)

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Dualid (ANTIULCER)

Property Description
Active ingredient Ranitidine Hydrochloride (Ranitidine)
Form Tablet, Effervescent tablet, Syrup, Injection
Pharmacological class Histamine H2-receptor antagonist (H2-blocker)
Common use Reduction of gastric acid secretion
Origin Synthetic small molecule

Defining Dualid's Composition and Class

Dualid is an anti-ulcer medication defined by its active pharmaceutical ingredient, Ranitidine Hydrochloride (Ranitidine). This compound is recognized globally and is classified as a Histamine H2-receptor antagonist, commonly referred to as an H2-blocker. Ranitidine is a synthetic single-ingredient product developed as an antisecretory agent to manage conditions influenced by excessive stomach acid. The H2-blocker class is noted for providing effective, sustained control over acid output, differing functionally from simple acid-neutralizing agents.

Drug Type, Forms, and Therapeutic Purpose

The active component, Ranitidine, is notable for being formulated into multiple dosage forms, including oral tablets, effervescent tablets, and a sterile solution for injection for parenteral use. While many medications in this class are offered only as oral tablets, Ranitidine's variety of forms ensures its core therapeutic action—the consistent reduction of gastric acid output—can be administered via oral or intravenous routes. The essential purpose of Dualid is to mitigate the corrosive effects of stomach acid by maintaining a lower acid environment in the upper gastrointestinal tract.

Regulatory References

  1. Food and Drug Administration (FDA) Drug Information
  2. National Library of Medicine (NIH)
Advertisements

What side effects are possible with Dualid (ANTIULCER)?

Possible Side Effects and Safety Information for Dualid (ANTIULCER)

This section describes the adverse reactions and safety constraints for Dualid as officially documented in governmental regulatory sources. The safety profile is structured to formally classify all known potential risks.

Adverse Reaction Scope

Element Regulatory Statement
Key Adverse Reaction Categories Side effects are formally classified by frequency of occurrence and the affected System Organ Class (SOC) according to international nomenclature.
Frequency Classification Adverse reactions are assigned to defined categories: Very Common (occurs in 1/10 patients), Common (1/100 to < 1/10), Uncommon, Rare, Very Rare, or Not Known (cannot be estimated from available data).
System-Organ Classes Involved Reactions are organized under systems such as Gastrointestinal Disorders (e.g., diarrhea, constipation, abdominal pain), Nervous System Disorders (e.g., headache, dizziness), and Skin and Subcutaneous Tissue Disorders.
Serious Adverse Reactions (SARs) The official label documents clinically significant, rare events that require immediate medical evaluation, such as anaphylactic reactions or specific organ toxicities like severe hepatotoxicity.
Population-Specific Safety Considerations Specific statements apply to defined patient groups, which may include the need for a lower starting dose in the geriatric population or particular monitoring for patients with severe renal or hepatic impairment.
Dose- or Exposure-Related Patterns Regulatory documents may note that the incidence of certain side effects can be more pronounced during the initial phase of treatment or that risks, such as specific nutrient deficiencies, may increase with long-term exposure (e.g., use beyond six months).
Safety-Related Restrictions or Limitations The drug is formally contraindicated in patients with known hypersensitivity to the components and in the presence of certain severe, uncompensated pre-existing conditions.

Safety Classifications (High-Level)

Regulatory Safety Summary:

  • Adverse reactions are systematically reported based on validated clinical trial and post-marketing data.
  • The label includes factual statements on necessary safety observation, such as periodic monitoring of specific laboratory parameters (e.g., liver function or mineral levels) during prolonged therapy.
  • Contraindications define strict limitations on the use of the medicine based on its established safety profile.

Connection to the Overall Safety Profile: The official safety information structures the understanding of the drug's risk by classifying every known adverse reaction by its frequency, type (SOC), and severity. This comprehensive classification system ensures that the full spectrum of potential safety issues, from common digestive discomforts to rare, serious events, is defined and communicated according to rigorous regulatory standards.

Advertisements

Overdose and Emergency Response

Dualid (ANTIULCER) Overdose and when to seek help

Official regulatory documents describe a ranitidine overdose as potentially leading to systemic effects, particularly concerning the Central Nervous System and Cardiovascular System.

Property Official Regulatory Statement
Documented overdose manifestations Symptoms may include agitation, confusion, drowsiness, slurred speech, hallucinations, flushing, dilated pupils, sweating, nausea, vomiting, and diarrhea.
Physiological systems affected Central Nervous System and Cardiovascular System. Cardiovascular effects include abnormal heartbeat (rapid or slow) and low blood pressure (hypotension).
Population-specific overdose notes Caution is advised in patients with impaired renal function, as the drug is primarily excreted by the kidney, which may increase the risk of systemic accumulation.

Immediate Actions and Management

When immediate medical help is required:

  • Seek emergency medical attention or contact a Poison Control Center right away for any suspected overdose.
  • Urgent assistance must be sought if the individual collapses, has a seizure, or is experiencing severe breathing difficulty.
  • Immediate attention is also mandated for symptoms of serious hypersensitivity or allergic reactions.

Management and Treatment:

  • Treatment for overdose is symptomatic and supportive, and official regulatory guidance does not specify a dedicated pharmacological antidote.
  • Supportive measures may include monitoring of vital signs, such as pulse and blood pressure, and managing specific symptoms that may arise.
Advertisements

Therapeutic Uses of Dualid (ANTIULCER)

What Dualid (ANTIULCER) Treats: Main Uses and Benefits

The therapeutic category Dualid belongs to is commonly used to manage gastroesophageal symptoms related to gastric acid, contributing to the relief of discomfort. These agents may be part of symptomatic management for conditions where symptoms may intensify temporarily, such as peptic ulcer disease, acid reflux, and general upper intestinal irritation. Antiulcer therapy provides support across domains involving heightened physiological activity and distress.

Supportive Management and Symptom Easing

Dualid is relevant when symptoms related to heightened physiological activity, such as burning pain or irritation, become intense or disruptive, and it is applied in addressing symptom clusters that may appear suddenly or fluctuate. The goal is to provide short-term symptomatic assistance during phases of increased distress, helping to ease the overall symptom load.

“This medication contributes to easing discomfort that interferes with daily functioning, supporting patients during difficult symptomatic episodes.”

This supportive role is considered relevant for managing conditions involving inflammatory or irritative processes where symptoms create noticeable physiological strain. Dualid helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Acute Gastrointestinal Discomfort

Regulatory References

  1. NIH LiverTox overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Dualid (Ranitidine)?

The eligibility profile for Dualid (Ranitidine) is defined by its regulatory history, absolute contraindications, and specific physiological restrictions established in official labeling.

Non-Eligibility and Contraindications

  • Market Withdrawal: Most prescription and over-the-counter oral formulations were requested for withdrawal by the FDA and suspended by the EMA due to the potential for the impurity N-nitrosodimethylamine (NDMA) to increase to unacceptable levels over time.
  • Contraindicated: Use is strictly prohibited for patients with known hypersensitivity to the drug or any component, and for those with a history of acute porphyria.

Conditional Eligibility and Restrictions

Population Group Eligibility Status (as per Official Labeling)
Renal Impairment Restricted: Mandatory dosage adjustment is required due to reduced drug clearance.
Hepatic Dysfunction Conditional: Caution is advised due to metabolism in the liver.
Pregnancy/Lactation Restricted: Use is permitted only if clearly essential.
Age Groups Established: Adults, adolescents, and pediatric patients from one month to 16 years of age. Caution for older adults due to decreased renal function.
Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Dualid is defined by documented pharmacokinetic patterns that modify drug exposure, primarily through two mechanisms: gastric pH alteration and competition for the renal organic cation transport system.


The H2-antagonist action can decrease the plasma concentration of drugs that require an acidic environment for proper absorption, including the antiretrovirals Atazanavir and Delavirdine, and the oncology agent Erlotinib. Conversely, exposure is increased for other drugs such as the hypnotics Triazolam and Midazolam. Due to these exposure alterations, the regulatory labeling for agents like Erlotinib specifies a mandatory timing separation window for co-administration.


Furthermore, Dualid is documented to reduce the renal excretion of Procainamide by inhibiting the organic cation transport system, resulting in officially elevated plasma levels of that drug. Close prothrombin time monitoring is required when co-administered with Warfarin, as altered prothrombin times have been reported. Simultaneous administration with potent antacids is reported to decrease Dualid's own absorption.


For specific populations, regulatory documents note minor, clinically insignificant alterations in Dualid’s pharmacokinetic parameters in patients with compensated cirrhosis (hepatic dysfunction).

Advertisements

Mechanism of Action

Irreversible Inhibition of the Acid Pump

Dualid acts primarily by engaging mechanisms that regulate acid production within the stomach's parietal cells. It specifically targets the H^+/ K^+-ATPase enzyme, commonly known as the Proton Pump, which represents the final common pathway for gastric hydrochloric acid ( HCl) secretion. The drug is activated in the acidic environment of the secretory canaliculus and subsequently forms a permanent covalent bond with cysteine residues on the enzyme, irreversibly inhibiting the pump's function.

Sustained Suppression and Systemic Effect

This molecular interaction initiates a mechanistic cascade leading to a sustained suppression of HCl output. The duration of this action is determined by the cellular rate of de novo synthesis of new H^+/ K^+-ATPase pumps, rather than the drug's systemic clearance. This targeted enzyme blockage results in a fundamental adjustment in gastric secretory dynamics, causing a measurable rise in luminal pH and altering the chemical environment of the gastric mucosa.

Advertisements

Dosage and Administration Information

How to Use Dualid (Ranitidine HCl) — Administration Guidelines

Dualid (Ranitidine Hydrochloride) administration is specified via Oral and Parenteral (Intravenous or Intramuscular) routes, supported by available dosage forms including tablets, effervescent tablets, oral solution, and solution for injection. The dosing regimen is highly dependent on the use phase (acute versus maintenance) and the formulation.


Dosing and Administration Protocol

Entity Administration Guideline
Route of Administration Approved for Oral, Intravenous (IV), and Intramuscular (IM) routes.
Dosing Schedule Acute Treatment: 150 mg (PO) twice daily or 300 mg (PO) once daily (at bedtime). Maintenance: 150 mg (PO) once daily.
Duration Acute Course: Typically 4 weeks, extendable to 8 weeks if required for healing.

Procedural and Population Constraints

Specific procedural steps are required for certain forms. The effervescent tablets must be dissolved completely in a full glass of water before administration. Oral dosing generally does not need to be timed in relation to food intake, but the 300 mg single dose is typically taken at bedtime.

A critical adjustment applies to patients with impaired renal function (creatinine clearance < 50 mL/min). In this population, the dosing frequency must be reduced. A common modification is 150 mg administered once every 24 hours. If a dose is missed, patients should take it as soon as possible, but skip the dose if the next scheduled dose is near (avoid doubling the dose).

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Dualid (Ranitidine)

The clinical research for Ranitidine, the active ingredient in Dualid, consists primarily of Randomized Controlled Trials (RCTs) and systematic reviews that have explored its use in various conditions linked to stomach acid. This overview helps explain what types of studies were conducted, what findings were observed, and where research remains limited. Findings describe group patterns, not personal outcomes; research does not determine whether an individual will respond similarly.


Evidence for Healing and Preventing Peptic Ulcer Disease (PUD)

This section will summarize the structure of Randomized Controlled Trials (RCTs) and long-term observational studies that examined outcomes related to ulcer healing and the incidence of recurrence in adult populations.

Research exploring the use of Ranitidine for peptic ulcer disease (PUD) primarily involved short-term, placebo-controlled clinical trials. Researchers monitored outcomes related to physical discomfort and directly measured the status of ulcer closure over defined time intervals, typically ranging from four to eight weeks. Maintenance studies observed patterns related to ulcer recurrence over follow-up durations extending for six months or longer.

Evidence primarily was studied for short-term healing of acute ulcers; long-term outcomes are not well characterized beyond the maintenance period. While extensive research exists, the results apply only to the populations studied. Comparative evidence sometimes reported distinctions in the resulting acid control when contrasted with other classes of acid suppressants.


Evidence for Managing Acid Reflux and Esophageal Damage (GERD)

This part will focus on the research exploring outcomes related to heartburn and acid reflux symptoms. It will outline the studies that assessed the endoscopic healing rate of damage to the esophageal lining (erosive esophagitis).

Studies exploring short-term symptom changes in Gastroesophageal Reflux Disease (GERD) involved controlled trials that monitored patient-reported outcomes describing perceived discomfort. Research examined outcomes capturing phases of heightened symptom activity, such as heartburn severity. Research explored short-term changes in symptoms over defined time intervals, typically four to twelve weeks.

Long-term effects are not fully established for continuous, non-erosive GERD management, as research exploring short-term symptom changes remains the focus. Data are still emerging for some extra-esophageal symptoms (like chronic cough) that may be associated with reflux, and certainty remains low in those specific areas.


Research for Rare, High-Acid Conditions

This section will describe the type of evidence available, primarily small-scale trials and physiological studies, that evaluated the drug's effect on gastric acid output in patients with rare, pathological hypersecretory conditions like Zollinger-Ellison Syndrome.

For rare conditions involving extreme, constant acid production, research was evaluated in patients with disorders such as Zollinger-Ellison Syndrome. The studies monitored outcomes related to systemic or functional imbalance by measuring the inhibition of gastric acid secretion itself. Due to the rarity of these conditions, the evidence is derived mostly from small-scale clinical trials, meaning comparative evidence is lacking.

Key Studies & References

  1. Ranitidine and Antiulcer Agents Overview (LiverTox - NIH)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dualid (ANTIULCER) (FAQ)


Q: How quickly can I expect to feel relief after taking Dualid?

Studies on the drug's activity indicate that the concentration needed to significantly reduce stomach acid is typically reached within 2 to 3 hours after taking a standard oral dose. This time frame reflects when the drug achieves its peak concentration in the body.


Q: How long does the effect of one dose of Dualid typically last?

Official information describes that following a single 150 mg oral dose, the drug's effect is sustained. It is documented to maintain acid-reducing concentrations for up to 12 hours after administration.


Q: Does Dualid affect the way my body absorbs vitamins or minerals?

Regulatory safety documents note that the long-term use of this class of medication is associated with the potential for reduced absorption of certain nutrients. Specifically, this may include vitamin B12, and may be associated with a risk of deficiency over time.


Q: What research evidence exists about Dualid's use in children or teenagers?

The recommendations for using this drug in pediatric patients, ranging from one month up to 16 years of age, are based on official documentation. These guidelines are informed by clinical studies conducted in adults, supplemented by specific data on how the drug is handled by the bodies of children and teenagers (pharmacokinetic data).


Q: Can Dualid be used to treat or prevent ulcers caused by taking NSAIDs like ibuprofen?

Yes, official documents indicate that prescription Ranitidine is labeled for the treatment and prevention of ulcers, including those associated with the use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs).


Q: Is Dualid considered safe for use during pregnancy?

The drug was previously described with a US FDA pregnancy category B classification. This category is used to describe a status where animal reproduction studies have not demonstrated a fetal risk, but adequate, controlled studies in pregnant women are not available.


Q: Is Dualid considered safe for use while breastfeeding?

Official regulatory findings state that the active ingredient in Dualid is excreted into human milk. The official patient information includes this finding.


Q: Does Dualid interact with blood thinners like warfarin?

Official drug interaction documents require close prothrombin time monitoring when this drug is co-administered with Warfarin. This is because altered prothrombin times, which relate to blood clotting, have been reported in these specific circumstances.


Q: Is Dualid the same as Tagamet or Pepcid?

Dualid (Ranitidine) belongs to the same general pharmacological class—the Histamine H2-receptor antagonists ( H2-blockers)—as Tagamet (Cimetidine) and Pepcid (Famotidine). However, they are distinct medicines with different active ingredients.


Q: Is it safe to use Dualid as a short-term solution for occasional heartburn?

Over-the-counter (OTC) versions of this drug are officially labeled for the relief and prevention of heartburn associated with acid indigestion and sour stomach. Regulatory labeling typically limits OTC use to a period of no more than 14 days.


Q: What conditions besides ulcers is Dualid commonly used to treat?

Approved uses extend beyond ulcers to include the treatment of Gastroesophageal Reflux Disease (GERD) and conditions where the stomach produces too much acid. This includes rare disorders such as Zollinger-Ellison syndrome.


Q: Are there any long-term side effects that are associated with using Dualid?

Regulatory documents describe the potential for certain risks to increase when the drug is taken for prolonged periods. These risks include an association with vitamin B12 deficiency and the potential for an increased risk of pneumonia, as noted in some studies.


Q: Does Dualid interact with alcohol?

Studies examining the co-administration of Ranitidine and alcohol have indicated that no clinically significant interaction occurred. This information is available in research summaries cited by authoritative medical resources.


Q: Are there any specific safety warnings related to men taking this medication (e.g., breast changes)?

Official documents note that occasional cases of impotence and loss of libido have been reported in male patients, though the incidence did not differ from that in the general population. No antiandrogenic activity, which can lead to breast changes, is described.


Q: Is Dualid effective for treating ulcers caused by H. pylori bacteria?

The drug is officially indicated for treating peptic ulcer disease (PUD). Ulcers associated with the H. pylori bacteria are typically addressed with a combination of several medications, and the drug is used as part of the overall regimen.


Q: If I miss a dose of Dualid, what is the protocol for catching up?

The official guidance defines the necessary steps for a missed dose. This protocol states that the dose should be taken as soon as possible, but advises skipping the dose to prevent taking a double dose if the next scheduled time is near.


Q: Is Dualid ever used for conditions other than acid reflux or ulcers?

Yes, regulatory and medical information confirms that the drug is also used to manage severe conditions involving stomach acid overproduction, such as Zollinger-Ellison syndrome. It has also been used in hospital settings for other gastrointestinal issues like upper GI bleeding.


Q: Can Dualid be taken with other anti-reflux medications like Sucralfate?

Official interaction screening indicates that no clinically significant interaction has been documented between Ranitidine (Dualid) and the anti-reflux medication Sucralfate.


Q: Does smoking affect the effectiveness of Dualid?

Research has examined the relationship between smoking and this drug class, indicating that smoking may slightly decrease the effectiveness of H2-receptor antagonists in reducing stomach acid. Smoking has also been shown to influence the healing of ulcers.


Q: Are there certain groups of people who are more likely to experience side effects from Dualid?

Regulatory documents note that rare cases of certain central nervous system (CNS) side effects, such as confusion or agitation, have been reported predominantly in severely ill elderly patients.


Q: Can Dualid affect how other medications for chronic conditions are metabolized?

The drug is documented to influence how the body handles other medications primarily through two mechanisms: changing the stomach's pH (acidity) and affecting the kidneys' process for eliminating drugs.


Q: Is Dualid safe for use in patients who have asthma?

Official documents list bronchospasm (a narrowing of the airways similar to an asthma attack) as a rare, serious hypersensitivity reaction that has been reported in connection with the medication.


Q: Can Dualid cause or worsen tiredness or fatigue?

The drug's official profile lists somnolence (drowsiness) as a rare central nervous system adverse reaction.


Q: Is it possible to take too much Dualid, and what are the general signs of overdose?

Regulatory documents instruct that in the event of an overdose, contact with medical help or a Poison Control Center is required immediately.

Advertisements

How should Dualid (ANTIULCER) be stored and disposed of?

How to Store and Dispose of Dualid (Ranitidine HCL)

Official regulatory documents define strict environmental controls for storing this medicine. It must be kept at room temperature, generally maintained below 25 C (77 F), and protected from excess heat and moisture.

The medication must remain in the tightly closed original container, and the desiccant must not be removed from the tablet bottle. Stability constraints require that unused tablets be discarded 3 months (90 days) after the bottle is first opened.

Disposal and Child Safety

All forms of the medicine must be stored strictly out of the sight and reach of children. Unused or expired product must not be disposed of via household trash or wastewater. Patients are instructed to consult a pharmacist for official guidance on discarding the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dualid (ANTIULCER) found in:

A-Z Index: